Randomized Double-Blind Cross-Over Study of Sinemet-Controlled Release (CR4 50/200) Versus Sinemet 25/100 in Parkinson's Disease
Sinemet-controlled release (CR4) consisting of 50 mg carbidopa/200 mg levodopa was compared with Sinemet 25/100 in 24 Parkinson€™s disease (PD) patients during a 16-week double-blind cross-over study. The mean age of the patients was 66.2 years, their mean duration of PD was 9.3 years. All of the patients had response fluctuations consisting mainly of the €˜wearing-off€™ phenomenon. Some of the patients also experienced the €˜on-off€™ phenomenon. All patients were evaluated using the unified Parkinson disease rating scale. The following significant differences were noted on Sinemet CR4. More patients noted a decrease in dyskinesias and response fluctuations; more patients experienced a decrease in stage when €˜on€™: more patients were €˜on€™ longer during the day. and more patients were globally improved. The mean number of doses per day were significantly less on Sinemet CR4 (mean 5.0, range 3-8) than on Sinemet 25/100 (mean 6.2, range 4-11 doses/day). The mean dose of levodopa in Sinemet CR4 was 1,186 ± 458 mg and the mean dose of carbidopa was 797 ± 115 mg. The mean dose of levodopa in Sinemet 25/100 was 873 ± 304 mg and the mean dose of carbidopa was 218 ± 76 mg. This study indicates that Sinemet CR4 is a useful addition for patients with response fluctuations.
Medical Subject Headings
Digital Object Identifier (DOI)
Lieberman, Abraham N.; Gopinathan, Govindan; Miller, Edith; Neophytides, Andreas; Baumann, Greg; and Chin, Linda, "Randomized Double-Blind Cross-Over Study of Sinemet-Controlled Release (CR4 50/200) Versus Sinemet 25/100 in Parkinson's Disease" (1990). Neurology. 104.